ERT Introduces Centralized DLCO Services for Respiratory Trials
Centralization reduces data variability, improves trial efficiencies
PHILADELPHIA, PA â ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today introduced its Centralized Services for assessing diffusing capacity of the lungs for carbon monoxide (DLCO) data in respiratory clinical trials. DLCO is valuable for determining clinical endpoints in Asthma, COPD, Idiopathic Pulmonary Fibrosis, and Cystic Fibrosis studies, as well as in clinical research for inhaled drugs or compounds impacting diffusing capacity. Repeated DLCO measurements aid in determining the efficacy or safety of drugs that are not obtainable by standard spirometry or imaging. Centralized DLCO Services integrates the EasyOne Pro device from ndd into ERT’s EXPERT Central private cloud platform for near real-time evaluation, notifications, expert overread, data reconciliation, and reporting. The solution includes ERT’s well recognized project assurance, data management, and training programs that enable investigative sites to optimize DLCO and spirometry collection. “Although DLCO tests are typically convenient and easy for patients to perform, independent studies have shown that DLCO measurements of the same patient in different labs can vary as much as 50%,” said Achim Schülke, Executive Vice President, Respiratory Solutions at ERT. “By centralizing DLCO collection with ERT’s solution, clinical trial sponsors benefit from higher data quality, reduced site burden, improved study oversight, and shortened timelines.” Clinical researchers can learn more about ERT’s Centralized DLCO Services in booth #509 at the Drug Information Association (DIA) Annual Meeting in Philadelphia, June 27-29 or at
www.ert.com/respiratory
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) â which includes patient-, clinician-, observer- and performance-reported outcomes â and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
